China’s Brain-Computer Interface Sector Reaches Critical Inflection Point in 2025

China’s brain-computer interface (BCI) industry reached a historic turning point in 2025, driven by a powerful convergence of state-level strategy, accelerated capital inflows, and breakthroughs in clinical technology. The sector has transitioned from a phase of experimental exploration to systematic industrial cultivation, establishing a distinct developmental path aimed at challenging global dominance in high-end medical technology.

The inclusion of BCI technology in the national "15th Five-Year Plan" as a strategic future industry marked a definitive elevation of the sector's status. This top-level design was swiftly met with regional execution, most notably by Shanghai, which established aggressive timelines for full clinical application by 2030. These policy signals have provided long-term certainty, transforming BCI from a fringe scientific pursuit into a focal point of national competitiveness.

Investor confidence has surged in tandem with policy clarity. Venture capital funding for the sector nearly quadrupled year-on-year, with significant capital moving toward high-barrier invasive technologies previously considered too risky. The market impact was immediate: the BCI theme index on the A-share market rose 55.27% year-to-date, significantly outperforming the broader Shanghai Composite Index.

Technologically, 2025 saw China narrow the gap with the U.S. through its first successful human trial for invasive BCI and the rapid clinical advancement of semi-invasive systems. While a technical and valuation gap remains compared to U.S. leaders like Neuralink, China is leveraging its massive clinical population and efficient supply chain to build an "asymmetric advantage," prioritizing medical necessity and motor function reconstruction as the primary routes to commercialization.

Policy and Capital Resonance

The defining characteristic of 2025 was the synchronization of government policy and private capital. Following a multi-departmental implementation opinion released in July, the central government formally designated BCI as one of six key directions for future industries in October. Local governments responded quickly; the Shanghai Action Plan for Cultivating the Future BCI Industry (2025-2030) set quantifiable targets, including the completion of clinical trials for at least five invasive or semi-invasive products by 2027.

This regulatory framework catalyzed a funding boom. According to IT Juzi data, as of November 2025, the sector recorded 16 financing events totaling RMB 983 million (US$135 million), a stark increase from the six events and RMB 201 million recorded in 2024.

Notably, the investment structure has matured. While over 75% of funding remains in early stages (Angel to Series A), investors are placing larger bets on "hard technology." Shanghai Stairway Medical Technology Co., Ltd. (Jieti Medical) completed a Series B financing round of RMB 350 million, setting a domestic record for invasive BCI funding. This shift indicates that top-tier capital is now willing to underwrite the high risks associated with complex medical equipment development.

Bridging the Technical and Valuation Gap

Despite the optimism, a disparity remains between China and the U.S. Industry analysts estimate a two-to-three-year technical lag between domestic players and Neuralink. While Neuralink has demonstrated 1,024-channel flexible electrode arrays, leading Chinese firms like Brain Tiger Technology Co., Ltd. (Nao Hu Technology) are currently operating at the 256-channel level. A significant valuation gap also persists, with Neuralink valued at approximately US$12 billion, nearly ten times that of BrainCo (Qiangnao Technology), one of China's highest-valued players.

However, domestic technology achieved critical milestones this year. In June, China conducted its first invasive BCI clinical trial. Furthermore, the "North Brain No. 1" (Bei Nao Yi Hao) system, a semi-invasive wireless solution, has been implanted in five patients with spinal cord injuries, with a more advanced "North Brain No. 2" scheduled for clinical verification in 2026.

Industry insiders argue that China possesses unique "asymmetric advantages." These include the world's largest patient pool—over 13 million stroke patients and 3 million with spinal injuries—and a clinical translation cycle of approximately 18 months, roughly half that of the U.S. Furthermore, robust manufacturing capabilities allow for significant cost control, a crucial factor for eventual mass adoption.

Medical Necessity Leads Commercialization

The commercial pathway for BCI in China has solidified around "medical necessity first." The medical health sector currently accounts for 56% of the downstream market. While non-invasive technologies still dominate with an 82% market share due to safety and lower regulatory hurdles, the industry consensus is that invasive and semi-invasive solutions offer the ultimate utility for severe neural damage.

Listed companies are accelerating their entry. Xiangyu Medical (Henan Xiangyu Medical Equipment Co., Ltd.) plans to launch 20-30 rehabilitation devices integrating BCI technology in 2025. Meanwhile, the NEO semi-invasive system, developed by Borui Kang (Beijing Borui Kang Technology Co., Ltd.) in collaboration with Tsinghua University, has entered the "Green Channel" for innovative medical device approval.

Clinical trials registered in 2025 show a heavy concentration on motor function reconstruction for stroke and spinal cord injury patients. This suggests that the industry is moving past theoretical "tech spectacles" to focus on proven medical value—specifically, the restoration of movement and communication capabilities.

Structural Challenges Ahead

While the "triple threat" of policy, capital, and technology has propelled the industry forward, significant hurdles remain for widespread adoption. The primary challenge lies in establishing a closed loop of "value proof."

Manufacturers face a rigorous "evidence barrier" in clinical trials, particularly for Class III invasive medical devices, which require long cycles and heavy investment. Subsequently, they face a "trust barrier" in convincing doctors to adopt new paradigms and a "payment barrier" in integrating these costly technologies into the medical insurance system.

In the consumer market, adoption remains slow. To move beyond niche applications like focus training and meditation, devices must achieve "invisibility" (seamless wearability) and offer indispensable functionality. Until these devices can integrate effortlessly into the broader consumer electronics ecosystem—such as VR/AR or smartphones—at a mass-market price point, the medical sector will remain the primary engine of growth.

As 2025 closes, the initial hype is settling into a pragmatic race for clinical validation. The most difficult phase of the ascent—proving economic and social value to regulators, insurers, and patients—has just begun.